Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
macusight.com

See what CB Insights has to offer

Founded Year

2003

Stage

Other Investors | Alive

About MacuSight

MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. As part of its unique product development philosophy, MacuSight also concentrates on the optimal delivery of these compounds into the eye. By combining its compounds with innovative delivery approaches, the company strives to optimize the efficacy, safety, convenience and cost-effectiveness of its product candidates.

MacuSight Headquarter Location

32980 Alvarado-Niles Road Suite 846

Palo Alto, California, 94587,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

MacuSight Patents

MacuSight has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/20/2004

9/8/2009

Visual system, Diseases of the eye and adnexa, Ophthalmology, Human cells, Disorders of sclera and cornea

Grant

Application Date

9/20/2004

Grant Date

9/8/2009

Title

Related Topics

Visual system, Diseases of the eye and adnexa, Ophthalmology, Human cells, Disorders of sclera and cornea

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.